Adipokines and Cardiovascular Disease Risk
Author Information
Author(s): Laura Pala, Matteo Monami, Silvia Ciani, Ilaria Dicembrini, Alessandro Pasqua, Anna Pezzatini, Paolo Francesconi, Barbara Cresci, Edoardo Mannucci, Carlo Maria Rotella
Primary Institution: AOUC, University of Florence
Hypothesis
The study aims to assess the relationship among adiponectin, RBP4, aFABP, and visfatin, and incident cardiovascular disease.
Conclusion
The study confirms that low adiponectin is associated with increased incidents of ischemic heart disease, but not cerebrovascular disease.
Supporting Evidence
- Circulating adiponectin levels were significantly lower in cases of ischemic heart disease compared to controls.
- Circulating RBP4 levels were significantly increased in cerebrovascular disease and decreased in ischemic heart disease compared to controls.
- Circulating aFABP levels were significantly increased in cerebrovascular disease.
- Circulating visfatin levels were significantly lower in cases of both cerebrovascular disease and ischemic heart disease.
Takeaway
This study found that certain proteins made by fat can help predict heart problems, especially low levels of a protein called adiponectin.
Methodology
A case-control study nested within a prospective cohort of 2945 subjects, comparing 18 patients with incident cardiovascular diseases to matched controls.
Potential Biases
Potential selection bias due to matching criteria.
Limitations
The small sample size of cases may limit the generalizability of the findings.
Participant Demographics
Subjects aged 40–75 years without known diabetes, with a mix of genders.
Statistical Information
P-Value
0.021 for adiponectin, 0.001 for RBP4, 0.041 for aFABP, 0.014 and 0.035 for visfatin.
Confidence Interval
2–161 for the risk of IHD per decrement of 1 μg/mL adiponectin.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website